Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.
André LacroixM D BronsteinJ SchopohlT DelibasiR SalvatoriY LiA BarkanN SuzakiL TauchmanovaC-E OrtmannS RavichandranS PetersennR PivonelloPublished in: Journal of endocrinological investigation (2020)
NCT01374906.